 |
|
|
Congress Alerts
|
Clinical Spotlights from the 2011 Oncology Annual Meeting
in Chicago
|
|
prIME Oncology invites you to view exciting news released from the 2011 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
7 JUNE 2011
|
| |
|
This expert interview with Heikki Joensuu, MD, from Helsinki University Central Hospital, Helsinki, Finland, and Peter Reichardt, MD, PhD, from HELIOS Klinikum Bad Saarow, Bad Saarow, Germany, along with an eNewsflash and downloadable slides, discusses the topic of gastrointestinal stromal tumors (GIST) focusing on the following data release:
Abstract LBA1: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
|
| |
|
|
| |
|
View the expert interview and opinion with Heikki Joensuu, MD, and Peter Reichardt, MD, PhD 
View eNewsflash
View downloadable slides
|
 |
|
8 JUNE 2011
|
| |
|
This expert interview with Jorge Marrero, MD, MS, from the University of Michigan, Ann Arbor, Michigan, United States, and Bruno Daniele, MD, PhD, from G. Rummo Hospital, Benevento, Italy, along with an eNewsflash and downloadable slides, discusses the topic of hepatocellular carcinoma (HCC), focusing on the following data release:
Abstract 4001: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction
|
| |
|
|
| |
|
View the expert interview and opinion with Jorge Marrero, MD, MS, and, Bruno Daniele, MD, PhD
View eNewsflash
View downloadable slides
|
 |
|
11 JUNE 2011
This expert interview with Giuseppe Saglio, MD, University of Turin, Italy, and Richard Larson, MD, University of Chicago, Illinois, United States, along with an eNewsflash and downloadable slides, discusses the topic of chronic myeloid leukemia (CML) focusing on the following data release:
Abstract 6511: Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.
Abstract 6502: The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up.
View the expert interview and opinion with Giuseppe Saglio, MD, and Richard Larson, MD
View eNewsflash
View downloadable slides
|
|
|
|
|
|
|
|
|
|
|
|
|
